Nifurtimox
- Generic Name
- Nifurtimox
- Brand Names
- Lampit
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N3O5S
- CAS Number
- 23256-30-6
- Unique Ingredient Identifier
- M84I3K7C2O
- Background
Chagas disease, caused by a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and humans in the Americas. It is commonly known as American Trypanosomiasis.
...
- Indication
Nifurtimox is indicated in pediatric patients under 18 weighing at least 2.5 kg. Continued approval of this drug for this indication is dependent upon confirmatory clinical trial results.
- Associated Conditions
- Chagas Disease
- Associated Therapies
- -
New Therapies and Biomarkers for Chagas Infection
- Conditions
- Interventions
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- University of Texas, El Paso
- Target Recruit Count
- 450
- Registration Number
- NCT03981523
- Locations
- 🇧🇴
Platform for the Comprehensive Care of Patients with Chagas Disease, Sucre, Bolivia
CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Universidad Autónoma de Bucaramanga
- Target Recruit Count
- 500
- Registration Number
- NCT02369978
- Locations
- 🇨🇴
Fundación Oftalmológica de Santander - Clínica Ardila Lulle (FOSCAL), Bucaramanga, Santander, Colombia
Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2
- Conditions
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 394
- Registration Number
- NCT01685827
- Locations
- 🇨🇬
CRT (Centre de Réference et de Traitement) Dipumba, Dipumba general hospital, Mbuji Mayi, East Kasai, Congo
🇨🇬HGR ISANGI hospital, Isangi, Province Orientale, Congo
🇨🇬Masi Manimba Hospital, Masi Manimba, Bandundu - DRC, Congo
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
- Conditions
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 112
- Registration Number
- NCT00601003
- Locations
- 🇺🇸
Connecticut Children's Hospital, Hartford, Connecticut, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Children's Medical Center, Dallas, Texas, United States
Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma
- Conditions
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2009-10-23
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 20
- Registration Number
- NCT00486564
- Locations
- 🇺🇸
St. Louis University/Cardinal Glennon Childrens Medical Center, St. Louis, Missouri, United States
🇺🇸University of Vermont/Vermont Children's Hospital, Burlington, Vermont, United States
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 280
- Registration Number
- NCT00146627
- Locations
- 🇨🇩
MSF-Belgium; PNLTHA, Epicentre, Isangi, Congo, The Democratic Republic of the
🇨🇩PNLTHA, STI, Epicentre, Mbuyi Maji, Congo, The Democratic Republic of the
🇨🇬MSF-Holland, Nkayi, RoC, Congo
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.